Melanoma antigen recognized by T cells 1 peptide-HLA-A2 complex (MART-1/HLA-A2 complex)

The Melanoma antigen recognized by T cells 1 peptide-HLA-A2 complex is formed when a short peptide from the Melan-A (MART-1) protein—a melanoma tumor-associated antigen—is presented by the class I MHC molecule HLA-A2 on the cell surface. Cytotoxic T lymphocytes recognize this complex and can selectively target and kill melanoma cells expressing it. Modified peptides with increased HLA-A2 affinity have been developed to enhance immunogenicity and serve as therapeutic cancer vaccines. The presence of this complex allows for both natural and engineered immune responses, including therapeutic antibodies that mimic T cell receptor specificity and peptide-based vaccine strategies. The most common form of this complex studied for immunotherapy involves modified Melan-A/MART-1 peptides (such as ELAGIGILTV or ALGIGILTV) bound to HLA-A2, enhancing their ability to stimulate an immune response against melanoma. The specificity and density of the MART-1/HLA-A2 complex on the tumor cell surface can be monitored using specialized antibodies or tetramer reagents. Therapies targeting this complex rely on its cancer-selective expression and restricted tissue distribution, factors improving both efficacy and safety. This molecular complex is a prototypical example of a peptide-MHC target in cancer immunotherapy and research.

Other names

Melan-A/MART-1 peptide-HLA-A2 complexMART-1/HLA-A2 complexMelan-A/HLA-A2 complexMelanoma antigen peptide-MHC class I complex

Induction of cytotoxic T cell response against melanoma cells through recognition of the peptide-HLA complex by T cell receptors and engineered antibodies. Immunotherapies include vaccines that stimulate these responses and antibodies that bind the complex to mark and destroy tumor cells.